SynthesisBiomedicines2023

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis.

Joe Q Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.